How do myasthenia gravis clinic nurses explain to a Spanish-speaking patient's family why pyridostigmine alone is not sufficient treatment for MG?

The family's confusion is understandable and follows directly from what they observe: the patient started pyridostigmine, the ptosis improved, the swallowing difficulty reduced, the limb weakness became more manageable — and now the neurologist is adding a second medication, and then possibly a third, despite the fact that the patient is already better. The explanation requires teaching what pyridostigmine actually does at the neuromuscular junction, and why what it does is fundamentally different from what immunosuppression does. Myasthenia gravis is caused by IgG autoantibodies — in 85 percent of generalized MG, specifically IgG1 and IgG3 antibodies directed against the alpha-1 subunit of the nicotinic acetylcholine receptor (AChR) on the postsynaptic muscle end plate. These antibodies impair NMJ function through three mechanisms: direct blockade of the acetylcholine binding site (preventing ACh from binding to the receptor even when it arrives at the cleft); complement-mediated destruction of the postsynaptic end-plate membrane (IgG1 and IgG3 activate the complement cascade, which attacks and simplifies the postsynaptic membrane folds, reducing the effective AChR surface area); and receptor internalization via cross-linking and endocytosis (IgG antibodies cross-link adjacent AChRs, triggering their internalization and degradation faster than the muscle can synthesize new receptors). The net result is that the total number of functional AChRs at the neuromuscular junction is reduced by 70 to 90 percent compared to a healthy NMJ. At a normal NMJ, a single nerve action potential releases far more acetylcholine quanta than are needed to trigger a muscle action potential — this redundancy is the 'safety factor.' In MG, the safety factor is eliminated: each nerve impulse releases acetylcholine that must bind to one of the drastically reduced number of available AChRs, and the end-plate potential generated may fall below the threshold for a muscle action potential. The result is fatigable weakness — the cardinal feature of MG — where muscles work initially but fail progressively as the gap between demand and NMJ capacity widens. Pyridostigmine works by inhibiting acetylcholinesterase, the enzyme that degrades acetylcholine in the synaptic cleft after it has bound its receptor. By inhibiting this enzyme, pyridostigmine slows the degradation of each ACh molecule, giving it more time to find and bind one of the remaining AChRs before being destroyed. This increases the probability that each quantum of released acetylcholine generates a successful receptor activation, partially restoring the end-plate potential amplitude. The symptom improvement is real. But pyridostigmine does not stop the antibodies from continuing to destroy AChRs. The autoimmune attack continues regardless of what happens in the synaptic cleft. Over time, without immunosuppression, the antibody-mediated AChR loss continues and the patient's underlying disease progresses — eventually reaching a level of receptor depletion that pyridostigmine's compensatory mechanism cannot overcome. Immunosuppression — corticosteroids, mycophenolate mofetil, azathioprine, or biologic agents such as rituximab — addresses the upstream cause: reducing the production of the AChR autoantibodies that are destroying the receptors. The distinction that clarifies the dual-therapy logic: pyridostigmine manages the consequence (too few AChRs available to be activated); immunosuppression addresses the cause (antibodies destroying AChRs faster than they can be replaced). Both are required because pyridostigmine cannot stop receptor loss and immunosuppression takes months to reduce antibody levels enough to meaningfully increase AChR density. The Spanish frame: 'La piridostigmina hace que el acetilcolina que se libera en la unión neuromuscular dure más tiempo antes de que se destruya — así tiene más oportunidad de encontrar uno de los receptores que quedan. Pero no detiene los anticuerpos que están destruyendo esos receptores. Sin el inmunosupresor, los receptores siguen perdiendo, y llega un momento en que la piridostigmina no puede compensar lo que se pierde. El inmunosupresor ataca la causa. La piridostigmina maneja la consecuencia. Las dos cosas son necesarias.'

How do myasthenia gravis clinic nurses explain to a Spanish-speaking patient's family why specific common medications are permanently dangerous in MG?

The family's confusion about medication restrictions in MG often follows the same pattern: the patient has been stable for months or years, feels well, and the neurologist or clinic nurse is telling them they can never take a class of antibiotics, or that even eye drops for glaucoma need to be changed. In a patient who appears healthy, this restriction sounds overly cautious. The explanation requires teaching why 'well-controlled MG' does not mean 'restored NMJ.' At a normal neuromuscular junction, each nerve action potential releases far more acetylcholine than is needed to trigger a muscle action potential — a large safety margin. In MG, even well-controlled MG, the antibody-mediated AChR depletion has reduced this safety margin to near zero. Treatment has stopped the progression and allowed symptoms to become manageable, but it has not restored the original AChR density to normal. The patient with MG in clinical remission is functionally compensated — the remaining AChRs are sufficient for normal daily activities — but there is essentially no reserve. A medication that impairs NMJ transmission by a small amount below the clinical threshold in a healthy person can, in a patient with near-zero NMJ reserve, drop the end-plate potential below the action potential threshold and produce clinical weakness or crisis. The medication classes that require permanent avoidance: Aminoglycoside antibiotics (gentamicin, tobramycin, amikacin, neomycin, streptomycin) impair calcium-dependent acetylcholine release from the presynaptic terminal at the NMJ. Calcium influx through voltage-gated calcium channels is required for ACh vesicle fusion with the presynaptic membrane and release into the cleft. Aminoglycosides reduce this calcium-dependent exocytosis, reducing the number of ACh quanta released per nerve impulse. In a healthy NMJ, this reduction leaves abundant ACh to still activate sufficient receptors. In MG, the presynaptic reduction combines with the postsynaptic AChR deficit to drop end-plate potential below threshold. Fluoroquinolone antibiotics (levofloxacin, moxifloxacin, ciprofloxacin) block voltage-gated potassium channels at the NMJ and have evidence of direct AChR channel blockade, reducing NMJ transmission efficiency. The magnitude of effect is subclinical in patients with normal NMJ reserve; in a patient with depleted AChR density, it is sufficient to produce exacerbation. Beta-blockers (including ophthalmic beta-blocker eye drops used for glaucoma — timolol, betaxolol) impair NMJ function through a mechanism that includes reduced end-plate potential amplitude; even the systemic absorption of topical ophthalmic beta-blockers is sufficient to worsen MG in susceptible patients. High-dose intravenous magnesium (including magnesium given for preeclampsia in an MG patient who becomes pregnant, or for cardiac arrhythmia) blocks the presynaptic voltage-gated calcium channels required for ACh vesicle exocytosis — the same mechanism as aminoglycosides, but often at higher magnitude, and capable of precipitating acute respiratory failure in an MG patient. Quinine and quinidine (older antiarrhythmics, found in tonic water in large amounts) block the neuromuscular junction potassium and sodium channels and are well-documented precipitants of MG exacerbation. Non-depolarizing neuromuscular blocking agents used in anesthesia (rocuronium, vecuronium, cisatracurium) act at the AChR — their mechanism is competitive blockade of the acetylcholine binding site. In a patient whose AChR density is already 70 to 90 percent reduced, even standard doses of non-depolarizing agents produce prolonged and unpredictable neuromuscular blockade, and residual paralysis after surgery is a documented risk. Anesthesiologists treating MG patients must be notified in advance, use the lowest effective doses, and monitor neuromuscular function through the postoperative period. What the family needs to understand: the medication list is not arbitrary caution for a patient who is well. It is an acknowledgment that the NMJ safety factor in MG, even well-controlled MG, is fundamentally different from that of a healthy person, and that the pharmacological effects of these medications — which are below the clinical threshold in healthy patients — can precipitate crisis in a patient who is compensated at near-zero reserve. A medical alert bracelet, a written medication list carried in the wallet, and a specific verbal statement to any urgent care, emergency, or surgical provider are non-negotiable components of MG management. The Spanish frame: 'Aunque el señor Andrés se sienta bien, la unión neuromuscular de sus músculos todavía tiene muchos menos receptores de acetilcolina que una persona sin miastenia. Hay medicamentos que reducen un poco la transmisión en esa unión — en una persona normal eso no causa síntomas porque tienen mucho margen. En él, ese pequeño bloqueo es suficiente para cruzar el umbral y provocar debilidad o crisis. Eso incluye algunos antibióticos, los betabloqueadores aunque sean en gotas para los ojos, el magnesio en dosis altas, y los relajantes musculares de la anestesia. El brazalete y la lista escrita no son exageración — son herramientas de seguridad porque no siempre habrá tiempo para explicarlo cuando se necesite.'

How do myasthenia gravis clinic nurses explain to a Spanish-speaking patient's family why myasthenic crisis triggered by a respiratory infection requires ICU admission and intubation?

The family's disbelief is predictable: the patient has been stable for years, has 'never been in the hospital for MG,' and a common cold is now the reason she is on a ventilator in the ICU. The explanation requires teaching what myasthenic crisis specifically is, why respiratory and bulbar muscle failure in MG is uniquely dangerous, and why MG patients cannot reliably detect their own impending respiratory failure. Myasthenic crisis is defined narrowly: it is the subset of MG exacerbation in which respiratory muscle weakness is severe enough to require mechanical ventilatory support — either elective intubation before acute distress or emergency intubation during acute respiratory failure. The definition is distinct from a severe MG flare affecting only limb or ocular muscles, which is a significant clinical problem but not a crisis. The respiratory muscles — diaphragm, external intercostals, accessory muscles — and the bulbar muscles — pharynx and larynx, required for maintaining a patent upper airway and preventing aspiration — share the same NMJ vulnerability as limb muscles in MG. Their AChR density is depleted by the same autoantibodies, and they are subject to the same fatigable weakness. But the consequence of respiratory and bulbar muscle failure is categorically different: a patient whose leg muscles are weak can sit or lie down; a patient whose respiratory muscles are weak cannot breathe adequately; a patient whose bulbar muscles are failing cannot protect the airway or swallow secretions. There is no 'rest and wait' for respiratory failure. Respiratory infections precipitate MG crisis through two converging mechanisms. The first is increased work of breathing: even mild bronchitis, airway edema, and mucus production require the respiratory muscles to work harder than normal. In a healthy patient, respiratory muscle reserve handles this effortlessly. In a patient whose respiratory muscle NMJ reserve is near-zero even during stability, an increased work of breathing that a healthy person manages without noticing can exceed what the weakened respiratory muscles can sustain. The second mechanism is disease-specific: systemic viral inflammation transiently upregulates AChR antibody production and can directly suppress NMJ function through inflammatory cytokines. The patient's underlying MG can worsen acutely during a respiratory infection through the immunological response itself, independent of the increased respiratory demand. The trajectory is characteristic and deceptive: unlike most causes of respiratory failure in which the patient feels acutely short of breath as the problem develops, MG respiratory failure can progress to the point of requiring intubation without the patient feeling dramatically dyspneic. The sensation of dyspnea is driven partly by chemoreceptors sensing elevated CO2. In MG respiratory failure, CO2 rises gradually as the fatiguing respiratory muscles reduce minute ventilation — and the patient may not feel severely dyspneic until hypercapnic respiratory failure is imminent. Bulbar muscle failure — inability to clear secretions, pharyngeal collapse, loss of laryngeal protection — can occur simultaneously and creates immediate aspiration risk. This is why the standard monitoring for a hospitalized MG patient at risk of respiratory failure is bedside forced vital capacity (FVC) measurement every four hours. FVC declines as respiratory muscle strength declines; the clinical trigger for elective intubation is typically FVC below 15 to 20 mL/kg of body weight, or a rapid decline trend, rather than the patient's subjective report of breathing difficulty. Elective intubation while the patient is alert and cooperative is dramatically safer than emergency intubation in an obtunded or hypoxic patient. 'Never been hospitalized for MG' means precisely that: over four years of stable disease, prior stressors had not crossed the threshold. This infection crossed it. The Spanish frame: 'La señora María Esperanza tiene miastenia que afecta los músculos que usamos para respirar y para mantener abierta la garganta, igual que afecta los músculos de los brazos y las piernas. Cuando tuvo el resfriado, los pulmones tuvieron que trabajar más para mover el aire, y la inflamación del virus empeoró la miastenia temporalmente — los dos factores juntos superaron lo que sus músculos podían hacer. La parte difícil es que los pacientes con miastenia no siempre sienten que les falta el aire antes de que los pulmones fallen de verdad — el CO₂ sube despacio y el cuerpo no da señales de alarma claras a tiempo. Por eso miramos la capacidad vital forzada cada pocas horas: es el número que nos dice cómo están los músculos respiratorios, no cómo se siente la paciente. Cuatro años sin hospitalización significaba que hasta ahora ningún estrés había cruzado ese umbral. Este resfriado sí lo cruzó.'

How do myasthenia gravis clinic nurses explain the difference between AChR-positive and MuSK-positive MG to Spanish-speaking patients?

Approximately 85 percent of patients with generalized myasthenia gravis have antibodies against the acetylcholine receptor (AChR-MG). About 5 to 8 percent have antibodies against muscle-specific kinase (MuSK-MG), and a small percentage are seronegative for both. The distinction matters clinically because MuSK-MG has several characteristics that differ from AChR-MG and affect how the nurse frames patient and family education. In MuSK-MG, the antibodies target MuSK — a receptor tyrosine kinase on the postsynaptic membrane that is essential for clustering AChRs at the NMJ during neuromuscular junction development and maintenance. Anti-MuSK IgG4 antibodies (the predominant subtype in MuSK-MG) do not activate complement and do not cross-link receptors for internalization; instead they disrupt AChR clustering by blocking the agrin-LRP4-MuSK signaling pathway, leading to AChR dispersal and NMJ disorganization. The clinical manifestations of MuSK-MG tend to be more severe and more heavily weighted toward bulbar and respiratory muscles than AChR-MG — prominent dysphagia, dysarthria, facial weakness, neck flexor weakness, and early respiratory involvement are characteristic features. This bulbar predominance increases the risk of aspiration and makes respiratory monitoring even more important than in typical AChR-MG. MuSK-MG responds less well to pyridostigmine and is often less responsive to standard immunosuppression with azathioprine and mycophenolate; rituximab has emerged as a preferred option for refractory MuSK-MG. The practical Spanish communication point: if a patient has MuSK-MG and has been told that pyridostigmine 'doesn't work as well' for them, this is not a failure of the medication or the diagnosis — it reflects a different underlying pathophysiology in which the problem is AChR clustering disruption rather than direct receptor blockade and destruction, and in which the compensatory mechanism pyridostigmine relies on (prolonging ACh availability to increase receptor binding probability) is less effective because the receptors, while present in adequate number, are not properly clustered at the end plate. The Spanish frame: 'Hay dos tipos principales de miastenia según cuál proteína atacan los anticuerpos. La más común ataca el receptor de acetilcolina directamente — la piridostigmina ayuda bastante en esos casos. La otra forma, que es menos común, ataca una proteína llamada MuSK que organiza los receptores en el músculo. Cuando la MuSK está bloqueada, los receptores no están bien organizados aunque haya suficientes — y la piridostigmina ayuda menos porque el problema no es cuánto acetilcolina llega sino cómo están dispuestos los receptores para recibirla. El tratamiento para esa forma requiere a veces medicamentos diferentes para suprimir el sistema inmune.'

What are the key Spanish phrases myasthenia gravis clinic nurses use when explaining pyridostigmine, medication safety, and crisis recognition to Spanish-speaking patients?

Four recurring communication moments where precise language consistently matters in the MG clinic. When explaining why pyridostigmine is not a cure: 'La piridostigmina bloquea la enzima que destruye el acetilcolina en la unión neuromuscular, para que cada molécula de acetilcolina tenga más tiempo de encontrar un receptor antes de desaparecer. Eso mejora los síntomas. Pero los anticuerpos que destruyen los receptores siguen activos — la piridostigmina no los detiene. Si no se tratan los anticuerpos con un inmunosupresor, los receptores siguen perdiéndose hasta que la piridostigmina ya no puede compensar. El inmunosupresor ataca la causa; la piridostigmina maneja la consecuencia de lo que los anticuerpos ya causaron.' (Pyridostigmine blocks the enzyme that destroys acetylcholine at the neuromuscular junction so each acetylcholine molecule has more time to find a receptor before disappearing. That improves symptoms. But the antibodies destroying the receptors remain active — pyridostigmine does not stop them. Without immunosuppression to treat the antibodies, receptors keep being lost until pyridostigmine can no longer compensate. The immunosuppressant attacks the cause; pyridostigmine manages the consequence of what the antibodies have already caused.) When explaining dangerous medications: 'Aunque se sienta bien, la unión neuromuscular de sus músculos todavía funciona con mucho menos receptores de lo normal — eso no cambia con el tratamiento, solo se estabiliza. Los medicamentos que bloquean aunque sea un poco la transmisión en esa unión — como algunos antibióticos, los betabloqueadores, y el magnesio en dosis altas — en una persona sana no causan síntomas porque tienen margen de sobra. En usted ese margen ya no existe, y ese bloqueo pequeño puede ser suficiente para provocar debilidad grave o crisis. Por eso la lista de medicamentos a evitar aplica siempre, aunque usted esté bien.' (Even when you feel well, the neuromuscular junction of your muscles still works with far fewer receptors than normal — that does not change with treatment, it only stabilizes. Medications that block NMJ transmission even slightly — like certain antibiotics, beta-blockers, and high-dose magnesium — in a healthy person cause no symptoms because they have reserve to spare. In you that reserve no longer exists, and that small blockade can be enough to cause severe weakness or crisis. That is why the medication avoidance list applies always, even when you are well.) When explaining myasthenic crisis risk during infection: 'Una infección respiratoria le exige más trabajo a los músculos de la respiración al mismo tiempo que la inflamación del virus empeora temporalmente la miastenia. Si los músculos de la respiración ya tienen poco margen por la miastenia, ese aumento de demanda puede superar lo que pueden hacer. Por eso cualquier infección respiratoria con síntomas que empeoran — más debilidad al tragar, más dificultad para respirar aunque sea leve, voz más nasal, tos más débil — es una señal de llamarnos ese día, no de esperar a ver cómo evoluciona.' (A respiratory infection demands more work from the breathing muscles at the same time that the virus's inflammation temporarily worsens myasthenia. If the breathing muscles already have little reserve because of MG, that increased demand can exceed what they can do. That is why any respiratory infection with worsening symptoms — more weakness swallowing, even mild difficulty breathing, more nasal voice, weaker cough — is a signal to call us that day, not to wait and see how it evolves.) When explaining why FVC is monitored rather than just asking 'how do you feel': 'Con la miastenia, los pulmones pueden empezar a fallar antes de que usted sienta que le falta el aire — el cuerpo puede aguantar un tiempo sin dar señales de alarma claras. Por eso medimos la capacidad vital forzada con una prueba sencilla de soplar — ese número nos dice directamente qué tan fuertes están los músculos respiratorios, sin depender de cómo se siente. Si ese número baja a cierto nivel, ponemos el apoyo respiratorio antes de que llegue a una crisis, porque actuar antes es mucho más seguro que actuar en urgencia.' (With myasthenia, the lungs can begin to fail before you feel short of breath — the body can manage for a time without giving clear warning signals. That is why we measure forced vital capacity with a simple blowing test — that number tells us directly how strong the respiratory muscles are, without depending on how you feel. If that number falls to a certain level, we provide respiratory support before a crisis develops, because acting early is much safer than acting in an emergency.)'

Spanish for myasthenia gravis clinic nurses — the patient whose brother cannot understand why pyridostigmine is a symptomatic treatment and immunosuppression is still required, the patient whose wife cannot understand why a common antibiotic nearly put him in the hospital, and the patient whose daughter cannot understand why a respiratory infection requires ICU admission when she has never been hospitalized for MG before

The myasthenia gravis clinic nurse’s communication challenge

The myasthenia gravis clinic nurse works in a disease whose mechanism is precise enough to explain completely — the biology of acetylcholine receptor autoimmunity is well-understood, the pharmacology of pyridostigmine is clear, the danger of specific medication classes follows directly from the mechanism — yet that mechanism is consistently misunderstood by patients and families who are doing their best to make sense of a disease they have never heard of before the diagnosis.

The first systematic communication failure in MG care is the pyridostigmine misunderstanding. The patient starts pyridostigmine and improves. The family concludes: the treatment is working, the disease is being treated, additional medications are unnecessary. What they have missed is that pyridostigmine treats the consequence of AChR loss — it prolongs the availability of acetylcholine at the synaptic cleft so the reduced number of remaining receptors can be more fully activated — but it does not address the autoimmune process destroying those receptors. Without immunosuppression, the antibody-mediated AChR destruction continues, and pyridostigmine’s compensatory mechanism is eventually overwhelmed. Immunosuppression is not a second medication added when pyridostigmine fails; it is the treatment of the underlying disease that pyridostigmine cannot reach.

The second systematic failure is the medication safety gap. Patients with well-controlled MG are repeatedly prescribed antibiotics, beta-blockers, or other drugs by urgent care clinics or other providers who do not know the MG diagnosis, or who know it but do not know which medications are contraindicated. The danger is not intuitive: why would a common antibiotic given for a sinus infection matter to a patient with a neuromuscular disease? The answer requires understanding that “well-controlled MG” does not mean “restored NMJ.” The neuromuscular junction safety factor — the large margin between the amount of acetylcholine released and the amount required to generate a muscle action potential — is near zero in MG even when symptoms are controlled. Medications that reduce NMJ transmission by a small amount below the clinical threshold in a healthy patient with abundant NMJ reserve can cross the action potential threshold in an MG patient with essentially none.

The third failure is crisis recognition. Myasthenic crisis — respiratory muscle weakness requiring mechanical ventilation — can develop rapidly from stable disease when a trigger crosses the patient’s individual threshold. The crisis is unexpected by the family precisely because the patient has been stable, and the trigger — a respiratory infection, a surgical procedure, a new medication — does not look like a cause of respiratory failure. Compounding the surprise: MG patients characteristically do not feel severely dyspneic until respiratory failure is imminent, because the rise in CO2 that signals impending failure is gradual, and subjective breathlessness lags behind objective forced vital capacity decline.

Three conversations from the myasthenia gravis clinic:

Scenario 1: Elena Castillo-Moreno — 52, elementary school principal from Albuquerque, New Mexico

Elena Castillo-Moreno had run Emilio Zapata Elementary School for eleven years. She managed a staff of forty-two, three hundred and twenty students, two dysfunctional copy machines, a school board that changed its attendance policy every six months, and a parking lot that held half the cars her staff drove. She was not a person who panicked, did not catastrophize, and did not, in her own estimation, have time to be seriously ill.

Eight months earlier she had noticed that by the end of the school day, her eyelids were drooping over her left eye in a way that photographs confirmed was not subtle. She had attributed it to exhaustion. When it persisted into morning, she saw her primary care physician. An edrophonium test had been markedly positive. AChR antibodies had returned at 14.2 nmol/L. The neurologist at the university MG clinic had confirmed generalized myasthenia gravis — ocular, bulbar, and proximal limb involvement. He had started pyridostigmine 60 mg every four hours, and over the following six weeks Elena had improved substantially: the ptosis resolved by noon most days instead of mid-morning, the swallowing difficulty that had been making dinners uncomfortable was largely gone, and she was climbing the three flights of stairs to her office without stopping on the second floor landing to rest.

At today’s clinic visit, the neurologist was recommending adding prednisone starting at 20 mg daily and titrating up over six weeks, with mycophenolate mofetil to follow. Her brother Ricardo, a software engineer from Santa Fe who had accompanied her today, had read extensively about MG since the diagnosis. He was skeptical.

“Elena está mejor. La piridostigmina funciona — eso ya quedó claro. ¿Por qué añadir más medicamentos que tienen efectos secundarios importantes cuando lo que tiene ya está funcionando? La prednisona tiene riesgos serios. ¿No es mejor esperar a ver si la piridostigmina es suficiente?” (Elena is better. The pyridostigmine is working — that is already clear. Why add more medications with significant side effects when what she has is already working? Prednisone has serious risks. Isn’t it better to wait and see if pyridostigmine is enough?)

The MG clinic nurse, Patricia Medina-Soto, had heard this question many times, and she appreciated that Ricardo had asked it clearly instead of simply arguing. She took a piece of paper from the desk and drew a simple diagram of the neuromuscular junction.

“Ricardo, su pregunta tiene todo el sentido. Para entender la respuesta, necesito mostrarle qué hace la piridostigmina en la unión entre el nervio y el músculo, y qué es lo que no hace.” (Ricardo, your question makes complete sense. To understand the answer, I need to show you what pyridostigmine does at the junction between the nerve and the muscle, and what it does not do.)

She explained the neuromuscular junction. When a nerve sends a signal to a muscle, she said, it releases a chemical called acetylcholine — ACh — into the tiny space between the nerve ending and the muscle. The ACh crosses that space and binds to receptors on the muscle surface. When enough receptors are activated simultaneously, the muscle generates an electrical impulse and contracts. At a normal NMJ, the nerve releases far more acetylcholine than is needed — the system has a large safety margin built in.

“En la miastenia,” she continued, “el sistema inmune produce anticuerpos que atacan esos receptores de acetilcolina en el músculo. Los anticuerpos bloquean el sitio donde el acetilcolina se une, activan el sistema del complemento que destruye la arquitectura de la superficie muscular, y hacen que los receptores se interioricen y se degraden más rápido de lo que el músculo puede reemplazarlos. El resultado: en una persona con miastenia, el número de receptores de acetilcolina disponibles es un 70 a 90 por ciento menor que en una persona sana.” (In myasthenia, the immune system produces antibodies that attack those acetylcholine receptors on the muscle. The antibodies block the site where acetylcholine binds, activate the complement system that destroys the surface architecture of the muscle, and cause the receptors to be internalized and degraded faster than the muscle can replace them. The result: in a person with myasthenia, the number of available acetylcholine receptors is 70 to 90 percent lower than in a healthy person.)

“Entonces con tan pocos receptores, ¿cómo es que Elena puede funcionar en absoluto?” Ricardo asked. (So with so few receptors, how can Elena function at all?)

“Exactamente esa es la pregunta correcta. Los músculos funcionan, pero con un margen muy reducido. El cuerpo compensa produciendo un poco más de acetilcolina, pero hay un límite para cuanto puede compensar. Con el tiempo o bajo estrés — enfermedad, ciruguía, cansancio intenso — los músculos empiezan a fallar más notablemente. Ahí es donde entra la piridostigmina.” (Exactly, that is the right question. The muscles work, but with very reduced margin. The body compensates by producing a bit more acetylcholine, but there is a limit to how much it can compensate. Over time or under stress — illness, surgery, intense fatigue — the muscles start failing more noticeably. That is where pyridostigmine comes in.)

She explained the mechanism. The same space between nerve and muscle that carries acetylcholine also contains an enzyme called acetylcholinesterase, whose job is to break down acetylcholine after it has done its work — so that the muscle does not remain permanently activated and can respond to the next signal. Pyridostigmine inhibits this enzyme, slowing the degradation of acetylcholine. Each molecule of released ACh now stays in the cleft longer and has more time to find and bind one of the remaining receptors before being destroyed.

“Eso es exactamente lo que hace la piridostigmina,” Patricia said. “Hace que cada molécula de acetilcolina funcione más eficientemente — dura más tiempo en la unión y tiene más oportunidad de encontrar un receptor disponible. Por eso Elena mejoró: la piridostigmina no aumentó los receptores, pero hizo que el acetilcolina que se libera active una mayor proporción de los receptores que quedan.” (That is exactly what pyridostigmine does. It makes each acetylcholine molecule work more efficiently — it lasts longer at the junction and has more opportunity to find an available receptor. That is why Elena improved: pyridostigmine did not increase the receptors, but it made the acetylcholine that is released activate a larger proportion of the receptors that remain.)

Ricardo followed the logic to its conclusion. “Entonces la piridostigmina trata los síntomas. Los receptores siguen siendo pocos.” (So pyridostigmine treats the symptoms. The receptors are still few.)

“Exactamente. Y la parte crítica: los anticuerpos que destruyen los receptores siguen activos. Sin inmunosupresor, esos anticuerpos siguen atacando. Con el tiempo — meses, años — los receptores siguen perdiéndose, y llega un momento en que la piridostigmina ya no puede compensar lo que se ha perdido. La curva empeora.” (Exactly. And the critical part: the antibodies that destroy the receptors remain active. Without immunosuppression, those antibodies keep attacking. Over time — months, years — the receptors keep being lost, and a point arrives where pyridostigmine can no longer compensate for what has been lost. The curve worsens.)

“¿Hay estudios que muestren que eso pasa?” (Are there studies showing that happens?)

“Sí. Los pacientes con miastenia no tratados con inmunosupresor tienen un mayor riesgo de crisis — episodios de debilidad muscular grave que pueden incluir los músculos de la respiración. La meta del tratamiento no es solo controlar los síntomas de hoy; es estabilizar la enfermedad a largo plazo para que Elena no llegue a un punto crítico dentro de dos años porque los receptores se fueron perdiendo gradualmente mientras la piridostigmina los mantenuía compensados sobre el papel pero la carga de anticuerpos seguía creciendo.” (Yes. Patients with myasthenia not treated with immunosuppression have a higher risk of crisis — episodes of severe muscle weakness that can include the breathing muscles. The goal of treatment is not just to control today’s symptoms; it is to stabilize the disease long-term so Elena does not reach a critical point in two years because receptors were gradually being lost while pyridostigmine kept them compensated on paper but the antibody burden kept growing.)

Elena had been listening with the quiet precision of someone who runs a complex organization. “¿Los esteroides reducen los anticuerpos?” (Do the steroids reduce the antibodies?)

“Sí, de dos formas. Primero, reducen la producción de nuevos anticuerpos al suprimir las células del sistema inmune que los hacen. Segundo, dan tiempo para que la densidad de receptores en los músculos aumente un poco a medida que la destrucción se desacelera. El mofetilo de micofenolato que seguirá a los esteroides tiene el mismo objetivo pero es más selectivo y tiene menos efectos secundarios a largo plazo.” (Yes, in two ways. First, they reduce the production of new antibodies by suppressing the immune system cells that produce them. Second, they give time for the receptor density in the muscles to increase slightly as the destruction slows. The mycophenolate mofetil that will follow the steroids has the same goal but is more selective and has fewer long-term side effects.)

Ricardo nodded slowly. “Entonces la piridostigmina hace que el poco acetilcolina que se libera funcione mejor, pero no detiene la destrucción de los receptores. Por eso necesita también el inmunosupresor — porque uno trata el síntoma y el otro trata la causa.” (So pyridostigmine makes the little acetylcholine that is released work better, but does not stop the destruction of the receptors. That is why she also needs the immunosuppressant — because one treats the symptom and the other treats the cause.)

“Exactamente eso. Lo dijo mejor que muchos libros de texto.” (Exactly that. You said it better than many textbooks.)

Scenario 2: Andrés Méndez-Reyes — 38, high school football coach from Laredo, Texas

Andrés Méndez-Reyes had been coaching varsity football at Martin High School for nine years. He was meticulous about his players’ physical condition — he tracked sleep, tracked nutrition, tracked injury recovery with the same attention he brought to defensive schemes — and since his MG diagnosis two years earlier he had brought the same methodical attention to his own disease management. He took his mycophenolate mofetil without fail, took his low-dose prednisone, showed up at every clinic appointment, and had not had a significant MG exacerbation in eighteen months.

Three weeks ago, he had developed acute sinusitis. His primary care physician was unavailable; he had gone to an urgent care clinic where a nurse practitioner had prescribed levofloxacin 750 mg for seven days. On the third day of the antibiotic, Andrés had noticed his right eyelid drooping significantly by mid-morning — worse than it had been in over a year. By day four, he was having mild difficulty swallowing thick foods. Day five, his wife Carolina, a nurse’s aide at a dialysis center, had insisted he call the MG clinic. The neurologist had instructed him to stop the levofloxacin immediately; the symptoms had resolved over the following three days. His sinusitis had cleared on its own.

Today’s visit was a follow-up to review what had happened and, critically, to prevent it from happening again. Carolina had come with him. She had a specific question she had been holding since the incident.

“Yo trabajo en diálisis, conozco bastantes medicamentos y sé que los fluoroquinolonas son antibióticos comunes que se usan en millones de personas sin problemas. ¿Cómo es posible que ese antibiótico casi lo manda a urgencias cuando su miastenia estaba tan bien controlada?” (I work in dialysis, I know quite a few medications and I know that fluoroquinolones are common antibiotics used in millions of people without problems. How is it possible that that antibiotic almost sent him to the emergency room when his myasthenia was so well-controlled?)

The MG clinic nurse, Jorge Carrillo-Vega, set aside the medication reconciliation form he had been completing. Carolina’s question was the exact right one, and answering it well would make the difference between Andrés understanding his medication restrictions as a rational safety protocol and seeing them as arbitrary rules he might be tempted to forget in future urgent situations.

“Carolina, la pregunta es perfecta y la respuesta es importante para que Andrés nunca vuelva a estar en esta situación. La clave está en entender qué significa ‘miastenia controlada’ en términos de lo que está pasando en sus músculos. Controlada no significa curada.” (Carolina, the question is perfect and the answer is important so Andrés is never in this situation again. The key is understanding what ‘controlled myasthenia’ means in terms of what is happening in his muscles. Controlled does not mean cured.)

He returned to the concept of the NMJ safety factor. In a healthy neuromuscular junction, he explained, the nerve releases many times more acetylcholine than is needed to trigger a muscle action potential. This abundance is intentional redundancy — a safety factor. Even if something reduces NMJ transmission efficiency by a small amount, there is enough reserve that the end-plate potential still exceeds the threshold for a muscle action potential, and no weakness results. The clinical effect of a modest NMJ impairment in a healthy person is zero — they feel nothing, do nothing differently, and the impairment is completely below the threshold of any observable consequence.

“En la miastenia de Andrés, aún tratada y con síntomas controlados, los receptores de acetilcolina en sus músculos todavía son un 70 a 90 por ciento menos de lo normal. El tratamiento estabiliza eso — evita que sigan perdiéndose y permite que el cuerpo funcione dentro de lo que queda — pero no restaura los receptores a niveles normales. El margen de seguridad que una persona sana tiene en la unión neuromuscular, en Andrés ese margen es casi cero.” (In Andrés’ myasthenia, even treated and with symptoms controlled, the acetylcholine receptors in his muscles are still 70 to 90 percent fewer than normal. Treatment stabilizes that — prevents them from continuing to be lost and allows the body to function within what remains — but it does not restore receptors to normal levels. The safety margin that a healthy person has at the neuromuscular junction, in Andrés that margin is near zero.)

Carolina made the connection immediately. “¿Y los fluoroquinolonas reducen la transmisión en esa unión?” (And fluoroquinolones reduce transmission at that junction?)

“Exactamente. Los fluoroquinolonas — la levofloxacina, la moxifloxacina, la ciprofloxacina — bloquean canales de potasio en la unión neuromuscular y tienen evidencia de que también bloquean los propios receptores de acetilcolina. En una persona con margen normal, ese bloqueo no produce ningún efecto — hay tanta reserva que sigue funcionando sin problema. En Andrés, ese mismo bloqueo — que en otra persona es indetectable — es suficiente para bajar el potencial de placa final por debajo del umbral necesario para generar un impulso en el músculo. El resultado es debilidad clínica. Eso es exactamente lo que pasó.” (Exactly. Fluoroquinolones — levofloxacin, moxifloxacin, ciprofloxacin — block potassium channels at the neuromuscular junction and have evidence of also blocking the acetylcholine receptors themselves. In a person with normal margin, that blockade produces no effect — there is enough reserve that it keeps working without a problem. In Andrés, that same blockade — which in another person is undetectable — is sufficient to drop the end-plate potential below the threshold needed to generate an impulse in the muscle. The result is clinical weakness. That is exactly what happened.)

Andrés had been listening with his coaching attention — the kind that identifies the system error, not just the symptom. “¿Sólo los fluoroquinolonas?” (Only fluoroquinolones?)

“No. Hay varias clases de medicamentos que funcionan por mecanismos similares. Los ami-noglicósidos — gentamicina, tobramicina, neomicina, estreptomicina — bloquean la liberación de acetilcolina del lado del nervio. El calcio es necesario para que las vesículas de acetilcolina se fusionen con la membrana del nervio y liberen su contenido. Los aminoglicósidos reducen esa liberación. En una persona con margen normal, el nervio libera de todas formas más que suficiente. En Andrés, la reducción puede ser crítica.” (No. There are several classes of medications that work by similar mechanisms. Aminoglycosides — gentamicin, tobramycin, neomycin, streptomycin — block the release of acetylcholine from the nerve side. Calcium is required for acetylcholine vesicles to fuse with the nerve membrane and release their contents. Aminoglycosides reduce that release. In a person with normal margin, the nerve releases more than enough anyway. In Andrés, the reduction can be critical.)

“¿Y otros medicamentos?” (And other medications?)

“Los betabloqueadores — y esto incluye las gotas para los ojos que se usan para el glaucoma como el timolol; la absorción sistémica de las gotas es suficiente para afectar la unión neuromuscular en un paciente con miastenia. El magnesio en dosis altas intravenoso, que se usa para la pre-eclampsia en el embarazo o para ciertas arritmias, bloquea los mismos canales de calcio del lado del nervio que los aminoglicósidos, y puede precipitar una crisis respiratoria aguda. La quinina — que está en el agua tónica en cantidades pequeñas pero en algunos medicamentos en dosis mayores — también deteriora la unión. Y los relajantes musculares no despolarizantes que usan en anestesia — el rocuronio, el vecuronio — actúan directamente bloqueando los receptores de acetilcolina. En un paciente con miastenia, dosis estándar de esos medicamentos producen un bloqueo neuromuscular prolongado e impredecible. El anestesiólogo tiene que saber antes de cualquier ciruguía.” (Beta-blockers — and this includes the eye drops used for glaucoma like timolol; the systemic absorption of the drops is sufficient to affect the neuromuscular junction in a myasthenia patient. High-dose intravenous magnesium, used for pre-eclampsia in pregnancy or for certain arrhythmias, blocks the same calcium channels on the nerve side as aminoglycosides and can precipitate acute respiratory crisis. Quinine — which is in tonic water in small amounts but in some medications at higher doses — also impairs the junction. And the non-depolarizing muscle relaxants used in anesthesia — rocuronium, vecuronium — work directly by blocking the acetylcholine receptors. In a myasthenia patient, standard doses of those medications produce prolonged and unpredictable neuromuscular blockade. The anesthesiologist must know before any surgery.)

Carolina processed what Jorge had described. She had seen enough at the dialysis center to understand that “drug interaction” was not always dramatic. “Entonces aunque Andrés esté bien, aunque haga sus actividades con normalidad y los números del laboratorio estén bien — la unión neuromuscular de sus músculos sigue siendo fundamentalmente diferente a la de una persona sin miastenia. No tiene ese margen de seguridad, aunque esté controlado.” (So even though Andrés is well, even though he does his activities normally and his lab numbers are good — the neuromuscular junction of his muscles is still fundamentally different from that of a person without myasthenia. He does not have that safety margin, even when controlled.)

“Exactamente. El control de la miastenia significa que los límites que tiene no le impiden hacer su vida. No significa que recuperó el margen que una persona sana tiene. Por eso la lista de medicamentos a evitar aplica siempre, no solo cuando tiene síntomas activos.” (Exactly. MG control means that the limitations he has do not prevent him from living his life. It does not mean he recovered the margin that a healthy person has. That is why the list of medications to avoid applies always, not only when he has active symptoms.)

Jorge produced three things: a written medication list, a card-sized summary for Andrés’s wallet, and a statement written in Spanish and English for him to give verbally to any urgent care, emergency, or surgical provider: “Tengo miastenia gravis. Algunos medicamentos comunes pueden provocarme una crisis. Por favor consulten con mi clínica de miastenia antes de prescribirme un antibiótico o usar anestesia.” (I have myasthenia gravis. Some common medications can trigger a crisis in me. Please consult with my myasthenia gravis clinic before prescribing me an antibiotic or using anesthesia.)

Andrés folded the wallet card and put it directly behind his driver’s license. He was, as he had always been, methodical about systems that kept his players — and now himself — safe.

Scenario 3: María Esperanza Trujillo-Vásquez — 64, retired postal worker from El Paso, Texas

María Esperanza Trujillo-Vásquez had worked thirty-one years for the United States Postal Service in El Paso, eighteen of them as a distribution clerk and thirteen as a supervisor. She had been diagnosed with AChR antibody-positive generalized myasthenia gravis eleven years ago after presenting with ptosis, diplopia, and difficulty chewing that had initially been attributed to dental problems. She had been hospitalized twice in the first two years of disease — once for a minor crisis managed without intubation, once for plasmapheresis when her symptoms were poorly controlled on oral medications. For the past four years, on pyridostigmine 60 mg four times daily and azathioprine 100 mg daily, she had been stable. No hospitalizations. She managed her symptoms, knew her triggers, and called the clinic when anything changed.

Six days ago she had developed what felt like an ordinary rhinovirus cold: runny nose, mild sore throat, low-grade temperature of 37.9°C. By day three the cold seemed to be improving. On day four, her daughter Adriana, an accountant who had dinner with her mother twice a week, noticed that María Esperanza’s voice sounded more nasal than usual and that she was having trouble finishing her sentences without pausing to swallow. Adriana had driven her to the emergency department at 10 PM. An arterial blood gas had shown pH 7.32, PaCO2 54 mmHg, PaO2 88 mmHg on room air. A bedside FVC was 780 mL — approximately 12 mL/kg for her weight. She had been intubated in the emergency department and transferred to the ICU.

She had now been on the ventilator for six days and was beginning to show signs of improvement. The ICU team had started plasmapheresis on day two; her pyridostigmine had been held during the acute phase and was being cautiously reintroduced. The MG clinic neurologist and nurse had come to the ICU to speak with Adriana before the morning family meeting.

Adriana was seated in a chair outside her mother’s room, holding a coffee she had stopped drinking. She had rehearsed her question on the drive in that morning.

“Mi mamá tiene miastenia desde hace once años. Nunca la habían hospitalizado por la miastenia en cuatro años. Era un resfríado común. ¿Cómo un resfríado la mandó a la UCI y a un respirador? Eso no tiene sentido.” (My mother has had myasthenia for eleven years. She had not been hospitalized for myasthenia in four years. It was a common cold. How did a cold send her to the ICU and a ventilator? That makes no sense.)

The MG clinic nurse, Rosa Delgado-Fuentes, had sat down beside Adriana before answering. “Adriana, el sentido que usted busca existe — hay una explicación directa para lo que le pasó a su madre, y quiero dársela completa porque es importante para el futuro también. Pero primero: su madre está mejorando. La plasmaféresis está funcionando. El equipo espera que pueda ser desconectada del respirador en los próximos días si la tendencia continúa.” (Adriana, the sense you’re looking for exists — there is a direct explanation for what happened to your mother, and I want to give it to you completely because it matters for the future too. But first: your mother is improving. The plasmapheresis is working. The team expects she can be removed from the ventilator in the coming days if the trend continues.)

Adriana exhaled and set the cold coffee on the floor beside the chair. “Cuénteme.” (Tell me.)

“La miastenia afecta todos los músculos que usan esa unión entre el nervio y el músculo que mencionamos antes — los de los brazos, las piernas, los ojos, la cara, la deglución. Pero también afecta los músculos de la respiración: el diafragma, los intercostales, los músculos accesorios que levantamos cuando respiramos hondo. Y los músculos de la garganta que mantienen la vía aérea abierta y permiten tragar.” (Myasthenia affects all the muscles that use that junction between nerve and muscle — those in the arms, legs, eyes, face, swallowing. But it also affects the breathing muscles: the diaphragm, the intercostals, the accessory muscles we lift when we take a deep breath. And the throat muscles that keep the airway open and allow swallowing.)

“Eso lo sabía. Lo que no entiendo es por qué ahora, después de cuatro años estable.” (I knew that. What I don’t understand is why now, after four stable years.)

“Hay dos mecanismos que convergen con las infecciones respiratorias en particular. El primero: el resfríado inflamó las vías respiratorias — produjo moco, edema de la mucosa, broncoespasmo leve. Eso significa que los músculos de la respiración tenían que trabajar más de lo normal para mover el mismo volumen de aire. En una persona sana, eso no es problema — los músculos tienen mucho margen. En la miastenia de su madre, esos músculos ya trabajaban cerca del límite de lo que podían hacer. El aumento de carga que el resfríado demandó los llevó por encima de ese límite.” (There are two mechanisms that converge with respiratory infections in particular. The first: the cold inflamed the airways — produced mucus, mucosal edema, mild bronchospasm. That means the breathing muscles had to work harder than normal to move the same volume of air. In a healthy person, that is not a problem — the muscles have a lot of margin. In your mother’s myasthenia, those muscles were already working near the limit of what they could do. The increased load the cold demanded pushed them above that limit.)

“¿Y el segundo mecanismo?” (And the second mechanism?)

“La inflamación sistémica de una infección viral puede empeorar temporalmente la miastenia por sí misma, independientemente del esfuerzo respiratorio. Las citoquinas inflamatorias pueden activar las células del sistema inmune que producen los anticuerpos contra los receptores de acetilcolina. Durante los días de la infección, el nivel de anticuerpos puede subir temporalmente — destruyendo más receptores de lo habitual. Los dos factores juntos — más trabajo respiratorio, menos capacidad de la unión neuromuscular — llegaron más allá de lo que sus músculos podían manejar.” (The systemic inflammation of a viral infection can worsen myasthenia temporarily by itself, independent of the respiratory effort. Inflammatory cytokines can activate the immune system cells that produce the antibodies against acetylcholine receptors. During the days of infection, the antibody level may rise temporarily — destroying more receptors than usual. The two factors together — more respiratory work, less neuromuscular junction capacity — went beyond what her muscles could manage.)

Adriana was trying to reconcile this with her memory of Monday evening. “Cuando la llevé a urgencias, no parecía que le faltara tanto el aire. Estaba hablando conmigo durante el trayecto. ¿Cómo estaba tan mal si no se veía tan mal?” (When I took her to the emergency room, she didn’t seem to be so short of air. She was talking to me during the drive. How could she be so sick if she didn’t look that sick?)

Rosa had been waiting for this question. It was the most clinically important moment in the conversation.

“Eso es una característica específica de la insuficiencia respiratoria en la miastenia. En muchas causas de falla respiratoria, las personas sienten que les falta el aire con anticipación suficiente para pedir ayuda. En la miastenia, eso no siempre ocurre. La sensación de falta de aire está impulsada en parte por los quimiorreceptores que detectan el CO2 en la sangre. Cuando los músculos de la respiración se van agotando y el volumen de aire por minuto va disminuyendo, el CO2 sube lentamente. El cuerpo lo tolera hasta cierto punto antes de dar una señal intensa de alarma. Para cuando se siente una disnea grave, el fallo respiratorio ya está avanzado.” (That is a specific characteristic of respiratory failure in myasthenia. In many causes of respiratory failure, people feel short of breath early enough to ask for help. In myasthenia, that does not always happen. The sensation of shortness of breath is driven in part by chemoreceptors detecting CO2 in the blood. When the breathing muscles are gradually exhausting and the minute ventilation is decreasing, CO2 rises slowly. The body tolerates it to a certain point before giving an intense alarm signal. By the time severe dyspnea is felt, respiratory failure is already advanced.)

“¿Por eso midiéron lo del aire en urgencias antes de que yo me diera cuenta de que era tan serio?” (Is that why they measured the air in the emergency room before I realized it was that serious?)

“Exactamente. La capacidad vital forzada — FVC — es la medida que usamos para monitorear la fuerza de los músculos respiratorios directamente, sin depender de cómo se siente el paciente. Cuando la FVC cae por debajo de cierto nivel — en adultos, alrededor de 15 a 20 mL por kilogramo de peso — es la señal de intubar de forma electiva, mientras el paciente está todavía despierto y cooperador y la intubación se puede hacer con calma. La FVC de su madre en urgencias era de 12 mL por kilogramo — ya estaba por debajo del umbral, y el gas arterial confirmó que el CO2 estaba subiendo. Por eso se intubó en urgencias esa noche.” (Exactly. The forced vital capacity — FVC — is the measure we use to monitor respiratory muscle strength directly, without depending on how the patient feels. When the FVC falls below a certain level — in adults, approximately 15 to 20 mL per kilogram of body weight — that is the signal to intubate electively, while the patient is still awake and cooperative and the intubation can be done calmly. Your mother’s FVC in the emergency room was 12 mL per kilogram — already below the threshold, and the arterial blood gas confirmed that CO2 was rising. That is why she was intubated in the emergency room that night.)

Adriana was quiet for a moment. “Y los cuatro años sin hospitalización — eso significaba que ninguna situación había cruzado ese umbral. Este resfríado sí lo cruzó.” (And the four years without hospitalization — that meant no situation had crossed that threshold. This cold did.)

“Exactamente. Cuatro años estable no significa que el riesgo desaparece. Significa que el tratamiento estaba manteniendo la enfermedad por debajo de ese umbral. El virus fue suficiente para cruzarlo. Lo que hay que hacer a futuro — y esto es importante — es que cualquier infección respiratoria de su madre, aunque parezca leve, requiere contactarnos ese mismo día si hay nuevos síntomas de miastenia: más dificultad para tragar, voz más nasal, tos más débil, cansancio al hablar. Esos son los signos de que los músculos bulbares y respiratorios están empezando a fallar. No esperamos a que le “falte el aire” porque para cuando eso ocurra puede ser tarde para intervenir sin urgencia.” (Exactly. Four stable years does not mean the risk disappears. It means the treatment was keeping the disease below that threshold. The virus was enough to cross it. What must be done in the future — and this is important — is that any respiratory infection your mother gets, even if it seems mild, requires calling us that same day if there are new myasthenia symptoms: more difficulty swallowing, more nasal voice, weaker cough, fatigue when talking. Those are the signs that the bulbar and respiratory muscles are beginning to fail. We do not wait for her to ‘feel short of breath’ because by the time that happens it may be too late to intervene without emergency.)

Adriana picked up the cold coffee, then put it down again. “O sea que cuando mi mamá tenga el próximo resfríado, la señal no es la falta de aire. La señal es que le cuesta más tragar o que la voz suena diferente.” (So when my mother gets the next cold, the signal is not shortness of breath. The signal is that she has more trouble swallowing or her voice sounds different.)

“Exactamente eso. Voz nasal, dificultad para tragar, tos débil, cansancio al hablar — ese día, no esperen. Nos llaman.” (Exactly that. Nasal voice, difficulty swallowing, weak cough, fatigue when talking — that day, do not wait. Call us.)